Increased risk of hospitalization for heart failure with newly prescribed dipeptidyl peptidase-4 inhibitors and pioglitazone using the Korean Health Insurance claims database

Sunghwan Suh, Gi Hyeon Seo, Chang Hee Jung, Mee Kyoung Kim, Sang Man Jin, You Cheol Hwang, byungwan lee, Jae Hyeon Kim

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Background: We assessed the association of dipeptidyl peptidase 4 inhibitors (DPP4i) with hospitalization for heart failure (HF) using the Korean Health Insurance claims database. Methods: We collected data on newly prescribed sitagliptin, vildagliptin, and pioglitazone between January 1, 2009 and December 31, 2012 (mean follow-up of 336.8 days) to 935,519 patients with diabetes (518,614 males and 416,905 females) aged 40 to 79 years (mean age of 59.4 years). Results: During the study, 998 patients were hospitalized for primary HF (115.7 per 100,000 patient-years). The incidence rate of hospitalization for HF was 117.7 per 100,000 per patient-years among patients on pioglitazone, 105.7 for sitagliptin, and 135.8 for vildagliptin. The hospitalization rate for HF was greatest in the first 30 days after starting the medication, which corresponded to a significantly higher incidence at days 0 to 30 compared with days 31 to 360 for all three drugs. The hazard ratios were 1.85 (pioglitazone), 2.00 (sitagliptin), and 1.79 (vildagliptin). The incidence of hospitalization for HF did not differ between the drugs for any time period. Conclusion: This study showed an increase in hospitalization for HF in the initial 30 days of the DPP4i and pioglitazone compared with the subsequent follow-up period. However, the differences between the drugs were not significant.

Original languageEnglish
Pages (from-to)247-252
Number of pages6
JournalDiabetes and Metabolism Journal
Volume39
Issue number3
DOIs
Publication statusPublished - 2015 Jan 1

Fingerprint

pioglitazone
Dipeptidyl-Peptidase IV Inhibitors
Health Insurance
Hospitalization
Heart Failure
Databases
Incidence
Pharmaceutical Preparations

All Science Journal Classification (ASJC) codes

  • Endocrinology, Diabetes and Metabolism

Cite this

Suh, Sunghwan ; Seo, Gi Hyeon ; Jung, Chang Hee ; Kim, Mee Kyoung ; Jin, Sang Man ; Hwang, You Cheol ; lee, byungwan ; Kim, Jae Hyeon. / Increased risk of hospitalization for heart failure with newly prescribed dipeptidyl peptidase-4 inhibitors and pioglitazone using the Korean Health Insurance claims database. In: Diabetes and Metabolism Journal. 2015 ; Vol. 39, No. 3. pp. 247-252.
@article{2d7fd6df7ea8459888f3508407e135ba,
title = "Increased risk of hospitalization for heart failure with newly prescribed dipeptidyl peptidase-4 inhibitors and pioglitazone using the Korean Health Insurance claims database",
abstract = "Background: We assessed the association of dipeptidyl peptidase 4 inhibitors (DPP4i) with hospitalization for heart failure (HF) using the Korean Health Insurance claims database. Methods: We collected data on newly prescribed sitagliptin, vildagliptin, and pioglitazone between January 1, 2009 and December 31, 2012 (mean follow-up of 336.8 days) to 935,519 patients with diabetes (518,614 males and 416,905 females) aged 40 to 79 years (mean age of 59.4 years). Results: During the study, 998 patients were hospitalized for primary HF (115.7 per 100,000 patient-years). The incidence rate of hospitalization for HF was 117.7 per 100,000 per patient-years among patients on pioglitazone, 105.7 for sitagliptin, and 135.8 for vildagliptin. The hospitalization rate for HF was greatest in the first 30 days after starting the medication, which corresponded to a significantly higher incidence at days 0 to 30 compared with days 31 to 360 for all three drugs. The hazard ratios were 1.85 (pioglitazone), 2.00 (sitagliptin), and 1.79 (vildagliptin). The incidence of hospitalization for HF did not differ between the drugs for any time period. Conclusion: This study showed an increase in hospitalization for HF in the initial 30 days of the DPP4i and pioglitazone compared with the subsequent follow-up period. However, the differences between the drugs were not significant.",
author = "Sunghwan Suh and Seo, {Gi Hyeon} and Jung, {Chang Hee} and Kim, {Mee Kyoung} and Jin, {Sang Man} and Hwang, {You Cheol} and byungwan lee and Kim, {Jae Hyeon}",
year = "2015",
month = "1",
day = "1",
doi = "10.4093/dmj.2015.39.3.247",
language = "English",
volume = "39",
pages = "247--252",
journal = "Diabetes and Metabolism Journal",
issn = "2233-6079",
publisher = "Korean Diabetes Association",
number = "3",

}

Increased risk of hospitalization for heart failure with newly prescribed dipeptidyl peptidase-4 inhibitors and pioglitazone using the Korean Health Insurance claims database. / Suh, Sunghwan; Seo, Gi Hyeon; Jung, Chang Hee; Kim, Mee Kyoung; Jin, Sang Man; Hwang, You Cheol; lee, byungwan; Kim, Jae Hyeon.

In: Diabetes and Metabolism Journal, Vol. 39, No. 3, 01.01.2015, p. 247-252.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Increased risk of hospitalization for heart failure with newly prescribed dipeptidyl peptidase-4 inhibitors and pioglitazone using the Korean Health Insurance claims database

AU - Suh, Sunghwan

AU - Seo, Gi Hyeon

AU - Jung, Chang Hee

AU - Kim, Mee Kyoung

AU - Jin, Sang Man

AU - Hwang, You Cheol

AU - lee, byungwan

AU - Kim, Jae Hyeon

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Background: We assessed the association of dipeptidyl peptidase 4 inhibitors (DPP4i) with hospitalization for heart failure (HF) using the Korean Health Insurance claims database. Methods: We collected data on newly prescribed sitagliptin, vildagliptin, and pioglitazone between January 1, 2009 and December 31, 2012 (mean follow-up of 336.8 days) to 935,519 patients with diabetes (518,614 males and 416,905 females) aged 40 to 79 years (mean age of 59.4 years). Results: During the study, 998 patients were hospitalized for primary HF (115.7 per 100,000 patient-years). The incidence rate of hospitalization for HF was 117.7 per 100,000 per patient-years among patients on pioglitazone, 105.7 for sitagliptin, and 135.8 for vildagliptin. The hospitalization rate for HF was greatest in the first 30 days after starting the medication, which corresponded to a significantly higher incidence at days 0 to 30 compared with days 31 to 360 for all three drugs. The hazard ratios were 1.85 (pioglitazone), 2.00 (sitagliptin), and 1.79 (vildagliptin). The incidence of hospitalization for HF did not differ between the drugs for any time period. Conclusion: This study showed an increase in hospitalization for HF in the initial 30 days of the DPP4i and pioglitazone compared with the subsequent follow-up period. However, the differences between the drugs were not significant.

AB - Background: We assessed the association of dipeptidyl peptidase 4 inhibitors (DPP4i) with hospitalization for heart failure (HF) using the Korean Health Insurance claims database. Methods: We collected data on newly prescribed sitagliptin, vildagliptin, and pioglitazone between January 1, 2009 and December 31, 2012 (mean follow-up of 336.8 days) to 935,519 patients with diabetes (518,614 males and 416,905 females) aged 40 to 79 years (mean age of 59.4 years). Results: During the study, 998 patients were hospitalized for primary HF (115.7 per 100,000 patient-years). The incidence rate of hospitalization for HF was 117.7 per 100,000 per patient-years among patients on pioglitazone, 105.7 for sitagliptin, and 135.8 for vildagliptin. The hospitalization rate for HF was greatest in the first 30 days after starting the medication, which corresponded to a significantly higher incidence at days 0 to 30 compared with days 31 to 360 for all three drugs. The hazard ratios were 1.85 (pioglitazone), 2.00 (sitagliptin), and 1.79 (vildagliptin). The incidence of hospitalization for HF did not differ between the drugs for any time period. Conclusion: This study showed an increase in hospitalization for HF in the initial 30 days of the DPP4i and pioglitazone compared with the subsequent follow-up period. However, the differences between the drugs were not significant.

UR - http://www.scopus.com/inward/record.url?scp=84932636107&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84932636107&partnerID=8YFLogxK

U2 - 10.4093/dmj.2015.39.3.247

DO - 10.4093/dmj.2015.39.3.247

M3 - Article

VL - 39

SP - 247

EP - 252

JO - Diabetes and Metabolism Journal

JF - Diabetes and Metabolism Journal

SN - 2233-6079

IS - 3

ER -